UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

CPT: pharmacometrics and systems pharmacology, 2024-03, Vol.13 (3), p.494-503

2024

Volltextzugriff (PDF)

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Molecular metabolism (Germany), 2018-12, Vol.18, p.3-14

2018

Volltextzugriff (PDF)

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Cell metabolism, 2022-09, Vol.34 (9), p.1234-1247.e9

2022

Volltextzugriff (PDF)

Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology

European journal of cancer (1990), 2014-02, Vol.50 (3), p.486-495

2014

Volltextzugriff (PDF)

Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

Journal of pharmaceutical sciences, 2010-03, Vol.99 (3), p.1582-1600

2010

Volltextzugriff (PDF)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

JCI insight, 2020-09, Vol.5 (17)

2020

Volltextzugriff (PDF)

Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009-03, Vol.877 (8), p.837-841

2009

Volltextzugriff (PDF)

A Phase I Study Evaluating the Effect of Everolimus on the Pharmacokinetics of Midazolam in Healthy Subjects

Journal of clinical pharmacology, 2013-04, Vol.53 (4), p.444-450

2013

Volltextzugriff (PDF)

Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects

Clinical and translational science, 2021-05, Vol.14 (3), p.1037-1048

2021

Volltextzugriff (PDF)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Clinical pharmacokinetics, 2021-08, Vol.60 (8), p.1049-1059

2021

Volltextzugriff (PDF)

Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: Application in the detection of colorectal cancer xenografts

mAbs, 2010-01, Vol.2 (1), p.67-72

2010

Volltextzugriff (PDF)

Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study

Clinical therapeutics, 2013-03, Vol.35 (3), p.215-225

2013

Volltextzugriff (PDF)

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Investigational new drugs, 2014-02, Vol.32 (1), p.123-134

2014

Volltextzugriff (PDF)

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2023-09, Vol.330 (11), p.1042

2023

Volltextzugriff (PDF)

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

The lancet. Diabetes & endocrinology, 2022-06, Vol.10 (6), p.418-429

2022

Volltextzugriff (PDF)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Clinical pharmacokinetics, 2022-07, Vol.61 (7), p.1057-1067

2022

Volltextzugriff (PDF)

Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide

Current medical research and opinion, 2024-04, Vol.40 (4), p.567-574

2024

Volltextzugriff (PDF)

Development and Validation of an Enzyme Linked Immunosorbent Assay for the Quantification of Carcinoembryonic Antigen in Mouse Plasma

Journal of immunoassay & immunochemistry, 2009-10, Vol.30 (4), p.418-427

2009

Volltextzugriff (PDF)

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies

The journal of clinical endocrinology and metabolism, 2024-01, Vol.109 (2), p.361-369

2024

Volltextzugriff (PDF)

Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test

The journal of clinical endocrinology and metabolism, 2024-05

2024

Volltextzugriff (PDF)

A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

Advances in therapy, 2023-08, Vol.40 (8), p.3434-3445

2023

Volltextzugriff (PDF)

Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group

Pharmaceutical research, 2023-07, Vol.40 (7), p.1601-1631

2023

Volltextzugriff (PDF)

58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Aktive Filter

ThemaDiabetes Mellitus

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Humans
(19)
Pharmacokinetics
(14)
Pharmacology & Pharmacy
(12)
Male
(11)
Adult
(10)
Animals
(8)
Diabetes Mellitus, Type 2 - Drug Therapy
(8)
Mice
(8)
Middle Aged
(8)
Clinical Trials
(7)
Diabetes
(7)
Drug Dosages
(7)
Female
(7)
Glucagon
(7)
Antidiabetics
(6)
Endocrinology & Metabolism
(6)
Everolimus
(6)
Pharmacology/toxicology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology

Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues

A Phase I Study Evaluating the Effect of Everolimus on the Pharmacokinetics of Midazolam in Healthy Subjects

Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: Application in the detection of colorectal cancer xenografts

Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide

Development and Validation of an Enzyme Linked Immunosorbent Assay for the Quantification of Carcinoembryonic Antigen in Mouse Plasma

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies

Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test

A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group

58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist

Aktive Filter

Suchergebnisse filtern